Opaganib demonstrated "potent inhibition" of the virus in an in vitro model of human lung bronchial tissue
() announced its COVID-19 treatment candidate showed promising results in laboratory test.
Opaganib demonstrated "potent inhibition" of SARS-CoV-2, the virus that causes COVID-19, in an in vitro model of human lung bronchial tissue.
It also compared favourably with remdesivir, the treatment developed by () and used in the US.
The candidate is under evaluation in global Phase 2/3 and US Phase 2 studies on humans for the treatment of severe COVID-19 pneumonia.
“We are accelerating progress toward our goal of generating a robust data package to potentially support emergency use authorisations for COVID-19,” said Mark L. Levitt, medical director at RedHill.
Shares advanced 10% to US$8.16 on Tuesday.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of RedHill Biopharma named herein, including the promotion by the Company of RedHill Biopharma in any Content on the Site, the Company receives...
FOR OUR FULL DISCLAIMER CLICK HERE